TY - JOUR
T1 - Identification of a T-cell receptor from a therapeutic murine T-cell clone
AU - Shilyansky, Joel
AU - Yang, James C.
AU - Custer, Mary C.
AU - Spiess, Paul
AU - Mixon, Arnold
AU - Cole, David J.
AU - Mulé, James J.
AU - Rosenberg, Steven A.
AU - Nishimura, Michael I.
PY - 1997/12/1
Y1 - 1997/12/1
N2 - Tumor-infiltrating lymphocytes (TIL) have been successfully used for the treatment of metastatic malignancies in clinical trials and in experimental animal models. Tumor-specific reactivity by TIL is mediated via receptors expressed on the surface of T cells (TcRs), which recognize tumor-associated antigens (TAA) presented in the context of MHC molecules on the surface of tumor cells. The current study was performed to identify the TcR α and β chains from a tumor-specific therapeutic TIL clone that can be used to develop a preclinical animal model for genetically modifying lymphocytes and hematopoietic progenitors with TcR genes. TIL 205 was generated from a subcutaneous implant of MCA-205 fibrosarcoma and at 21 days was cloned by limiting dilution. TIL clone 8, obtained from a culture seeded at one cell/well, mediated specific lysis and specific secretion of γ-interferon to MCA-205 and WP6, a subclone of MCA 205. No reactivity was observed against other syngeneic sarcoma lines. Anchor polymerase chain reaction analysis determined that antigen recognition by clone 8 was mediated by a TcR consisting of Vα3/Jα27 and Vβ8.2/Dβ2.1/Dβ2.4. Immunofluorescent staining with Vβ subfamily specific monoclonal antibodies revealed that >95% of the T cells in TIL clone 8 expressed Vβ8.2, confirming that TIL clone 8 was indeed a clone. In contrast, -30% of the T cells in the parental TIL 205 expressed Vβ8.2. The transfer of as few as 500,000 TIL clone 8 cells in conjunction with the systemic administration of recombinant human interleukin-2 mediated regression of established 3-day WP6 lung metastases. Thus, clone 8 recognizes a biologically relevant tumor rejection antigen, making the Vα3/Jα27- Vβ8.2/Dβ2.1/Jβ2.4 TcR isolated from this clone useful as a probe for cloning the tumor-rejection antigen in the WP6 tumor as well as modeling, in mice, the TcR-based gene therapies being developed for humans.
AB - Tumor-infiltrating lymphocytes (TIL) have been successfully used for the treatment of metastatic malignancies in clinical trials and in experimental animal models. Tumor-specific reactivity by TIL is mediated via receptors expressed on the surface of T cells (TcRs), which recognize tumor-associated antigens (TAA) presented in the context of MHC molecules on the surface of tumor cells. The current study was performed to identify the TcR α and β chains from a tumor-specific therapeutic TIL clone that can be used to develop a preclinical animal model for genetically modifying lymphocytes and hematopoietic progenitors with TcR genes. TIL 205 was generated from a subcutaneous implant of MCA-205 fibrosarcoma and at 21 days was cloned by limiting dilution. TIL clone 8, obtained from a culture seeded at one cell/well, mediated specific lysis and specific secretion of γ-interferon to MCA-205 and WP6, a subclone of MCA 205. No reactivity was observed against other syngeneic sarcoma lines. Anchor polymerase chain reaction analysis determined that antigen recognition by clone 8 was mediated by a TcR consisting of Vα3/Jα27 and Vβ8.2/Dβ2.1/Dβ2.4. Immunofluorescent staining with Vβ subfamily specific monoclonal antibodies revealed that >95% of the T cells in TIL clone 8 expressed Vβ8.2, confirming that TIL clone 8 was indeed a clone. In contrast, -30% of the T cells in the parental TIL 205 expressed Vβ8.2. The transfer of as few as 500,000 TIL clone 8 cells in conjunction with the systemic administration of recombinant human interleukin-2 mediated regression of established 3-day WP6 lung metastases. Thus, clone 8 recognizes a biologically relevant tumor rejection antigen, making the Vα3/Jα27- Vβ8.2/Dβ2.1/Jβ2.4 TcR isolated from this clone useful as a probe for cloning the tumor-rejection antigen in the WP6 tumor as well as modeling, in mice, the TcR-based gene therapies being developed for humans.
KW - T-cell clone
KW - T-cell receptor
UR - http://www.scopus.com/inward/record.url?scp=0031437864&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031437864&partnerID=8YFLogxK
U2 - 10.1097/00002371-199707000-00001
DO - 10.1097/00002371-199707000-00001
M3 - Article
C2 - 9220314
AN - SCOPUS:0031437864
SN - 1053-8550
VL - 20
SP - 247
EP - 255
JO - Journal of Immunotherapy
JF - Journal of Immunotherapy
IS - 4
ER -